SCIENCE NEWS Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase III Trial of Previously-Treated Patients with Metastatic Melanoma
Bristol-Myers Squibb Company announced positive results from a Phase III randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab. [Press release from Bristol-Myers Squibb Company discussing online prepublication in the New England Journal of Medicine]SPRYCEL® (Dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec® in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced Phase III study results in which SPRYCEL (dasatinib) 100 mg once daily demonstrated a superior rate of confirmed complete cytogenetic response compared to Gleevec® (imatinib mesylate). [Press release from Bristol-Myers Squibb Company discussing online prepublication in the New England Journal of Medicine] New Data Show Novartis Drug Tasigna® Surpasses Glivec® in Slowing Disease Progression for Newly Diagnosed CML Patients
Novartis announced 18-month results (median follow-up) showing that Tasigna® (nilotinib) significantly surpasses Glivec® (imatinib) in slowing disease progression in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase. [Press release from Novartis AG discussing online prepublication in the New England Journal of Medicine] Study Finds New Pattern in DNA Methylation, with Implications for Cancer, Stem Cell Lines
Using high-throughput DNA sequencing to study sites on DNA where high levels of methylation occur, a team of scientists discovered a relationship between methylation and the positioning of nucleosomes, which compact and regulate access to DNA in the nucleus of a cell. [Press release from the University of California, Los Angeles discussing online prepublication in Nature] Faulty Gene Stops Cell ‘Antennae’ From Transmitting
An international group of researchers has identified the genetic cause of an inherited condition that causes severe fetal abnormalities. [Press release from the University of California, San Diego discussing online prepublication in Nature Genetics] Cleveland Clinic Researchers Develop Prototype Vaccine to Prevent Breast Cancer
A first-of-its-kind vaccine to prevent breast cancer has shown overwhelmingly favorable results in animal models. [Press release from the Cleveland Clinic's Lerner Research Institute discussing online prepublication in Nature Medicine] Study of MicroRNA Helps NIH Scientists Unlock Secrets of Immune Cells
Researchers looked at mouse immune cells and examined the types, amount, and activity of microRNAs, genetic components that help regulate the production of proteins. [Press release from the National Institutes of Health discussing online prepublication in Immunity] Immune System Helps Transplanted Stem Cells Navigate in Central Nervous System
By discovering how adult neural stem cells navigate to injury sites in the central nervous system, researchers have helped solve a puzzle in the creation of stem cell-based treatments: How do these cells know where to go? [Press release from the University of California, Irvine discussing Proceedings of the National Academy of Sciences USA] Idera Pharmaceuticals Announces Publication of Preclinical Data on Cancer Immunotherapy with its Dual Agonist of Toll-like Receptors 7 and 8
Idera Pharmaceuticals, Inc. announced the publication of data from studies of a dual agonist of Toll-like Receptor 7 (TLR7) and TLR8 in preclinical models of cancer. [Press release from Idera Pharmaceuticals, Inc. discussing online prepublication in Molecular Cancer Therapeutics] Blocking DNA Repair Protein Could Lead to Targeted, Safer Cancer Therapy
Researchers at the University of Pittsburgh Cancer and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells. [Press release from the University of Pittsburgh discussing online prepublication in Science Signaling] Alnylam Presents Preliminary Phase I Data at American Society of Clinical Oncology Meeting for ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers
Alnylam Pharmaceuticals, Inc. announced preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. [Press release from Alnylam Pharmaceuticals, Inc. discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology] New Non-Small Cell Lung Cancer Drug Creates Stir
Crizotinib, an inhibitor of anaplastic lymphoma kinase has demonstrated the ability to shrink tumors in about 90% of patients with advanced non-small cell lung cancer. [Press release from MedPage Today discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology] Green Tea Extract Appears to Keep Cancer in Check in Majority of CLL Patients
An extract of green tea appears to have clinical activity with low toxicity in chronic lymphocytic leukemia (CLL) patients who used it in a phase II clinical trial. [Press release from the Mayo Clinic discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology] Experimental Targeted Therapy Shows Early Promise Against Medulloblastomas – A Type of Childhood Brain Cancer
Researchers report the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor. [Press release from St. Jude Children’s Research Hospital discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology] NewLink Genetics' HyperAcute® Immunotherapy Phase II Study Shows Promise in Disease Free and Overall Survival for Resectable Pancreatic Cancer
NewLink Genetics Corporation announced positive Phase II clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. [Press release from PR Newswire discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology] Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma
The goals of the study were to evaluate the over-all safety and efficacy of intravenous infusions of Rexin-G, a tumor-targeted retrovector bearing a cytocidal anti-cyclin G1 construct, in chemo-therapy-resistant bone and soft tissue sarcoma. [Press release from Epeius Biotechnologies Corporation discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology] CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Ipilimumab, with or without a glycoprotein 100 (gp100) peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. [N Engl J Med] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. [N Engl J Med] Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia. [N Engl J Med] Relationship Between Nucleosome Positioning and DNA Methylation
Researchers report a genome-wide nucleosome positioning analysis of Arabidopsis thaliana using massively parallel sequencing of mononucleosomes. [Nature] Structural Basis for 5'-Nucleotide Base-Specific Recognition of Guide RNA by Human AGO2
This study provides structural evidence for nucleotide-specific interactions in the middle domain of eukaryotic Argonaute proteins (AGOs) and explains the observed preference for U or A at the 5' end of miRNAs. [Nature] Mutations in TMEM216 Perturb Ciliogenesis and Cause Joubert, Meckel and Related Syndromes
Joubert syndrome (JBTS), related disorders and Meckel syndrome (MKS) are ciliopathies. Researchers now report that MKS2 and CORS2 (JBTS2) loci are allelic and caused by mutations in TMEM216, which encodes an uncharacterized tetraspan transmembrane protein. [Nat Genet] An Autoimmune-Mediated Strategy for Prophylactic Breast Cancer Vaccination
Alpha-lactalbumin vaccination may provide safe and effective protection against the development of breast cancer for women in their post-child-bearing, premenopausal years, when lactation is readily avoidable and risk for developing breast cancer is high. [Nat Med] Regulation of MicroRNA Expression and Abundance During Lymphopoiesis
Data provide a comprehensive map of immunity's microRNome and reveal the underlying epigenetic and transcriptional forces that shape miRNA homeostasis. [Immunity] Peripheral Transvenular Delivery of Adeno-Associated Viral Vectors to Skeletal Muscle as a Novel Therapy for Hemophilia B
Researchers adapted an intravascular delivery system of adeno-associated viral vectors encoding the factor IX transgene to skeletal muscle of hemophilia B dogs. [Blood]
| 
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
